Efficacy and Safety of Transdermal Methylphenidate for Cancer-Related Fatigue
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
To investigate the efficacy of sustained-release, transdermal methylphenidate compared to a placebo.
In reducing fatigue, increasing activity levels, and sustaining steady wakefulness throughout the day. The outcome measure will be BFI and ESS based self-reporting of the reduction of numeric rating scale on fatigue level and sleepiness, combined with objective measurement of increased activity intensity scores monitored by actigraphy.
for 10 days
Natalie Moryl, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board